Valentina Topić Vučenović1, Zvezdana Rajkovača2, Dijana Jelić3, Dragi Stanimirović2, Goran Vuleta2, Branislava Miljković4, Katarina Vučićević4. 1. Department of Pharmacy, Faculty of Medicine, University of Banja Luka, Save Mrkalja 14, 78000, Banja Luka, Bosnia and Herzegovina. valentina.topic.vucenovic@med.unibl.org. 2. Institute of Nuclear Medicine and Thyroid Gland Disease, University Clinical Centre of the Republic of Srpska, 12 beba bb, 78000, Banja Luka, Bosnia and Herzegovina. 3. Department of Pharmacy, Faculty of Medicine, University of Banja Luka, Save Mrkalja 14, 78000, Banja Luka, Bosnia and Herzegovina. 4. Department of Pharmacokinetics and Clinical Pharmacy, University of Belgrade - Faculty of Pharmacy, Vojvode Stepe 450, Belgrade, 11000, Serbia.
Abstract
PURPOSE: Radioiodine (131I) therapy is the common treatment option for benign thyroid diseases. The objective of this study was to characterize 131I biokinetics in patients with benign thyroid disease and to investigate and quantify the influence of patients' demographic and clinical characteristics on intra-thyroidal 131I kinetics by developing a population model. METHODS: Population pharmacokinetic analysis was performed using a nonlinear mixed effects approach. Data sets of 345 adult patients with benign thyroid disease, retrospectively collected from patients' medical records, were evaluated in the analysis. The two-compartment model of 131I biokinetics representing the blood compartment and thyroid gland was used as the structural model. RESULTS: Results of the study indicate that the rate constant of the uptake of 131I into the thyroid (ktu) is significantly influenced by clinical diagnosis, age, functional thyroid volume, free thyroxine in plasma (fT4), use of anti-thyroid drugs, and time of discontinuation of therapy before administration of the radioiodine (THDT), while the effective half-life of 131I is affected by the age of the patients. Inclusion of the covariates in the base model resulted in a decrease of the between subject variability for ktu from 91 (3.9) to 53.9 (4.5)%. CONCLUSIONS: This is the first population model that accounts for the influence of fT4 and THDT on radioiodine kinetics. The model could be used for further investigations into the correlation between thyroidal exposure to 131I and the outcome of radioiodine therapy of benign thyroid disease as well as the development of dosing recommendations.
PURPOSE:Radioiodine (131I) therapy is the common treatment option for benign thyroid diseases. The objective of this study was to characterize 131I biokinetics in patients with benign thyroid disease and to investigate and quantify the influence of patients' demographic and clinical characteristics on intra-thyroidal 131I kinetics by developing a population model. METHODS: Population pharmacokinetic analysis was performed using a nonlinear mixed effects approach. Data sets of 345 adult patients with benign thyroid disease, retrospectively collected from patients' medical records, were evaluated in the analysis. The two-compartment model of 131I biokinetics representing the blood compartment and thyroid gland was used as the structural model. RESULTS: Results of the study indicate that the rate constant of the uptake of 131I into the thyroid (ktu) is significantly influenced by clinical diagnosis, age, functional thyroid volume, free thyroxine in plasma (fT4), use of anti-thyroid drugs, and time of discontinuation of therapy before administration of the radioiodine (THDT), while the effective half-life of 131I is affected by the age of the patients. Inclusion of the covariates in the base model resulted in a decrease of the between subject variability for ktu from 91 (3.9) to 53.9 (4.5)%. CONCLUSIONS: This is the first population model that accounts for the influence of fT4 and THDT on radioiodine kinetics. The model could be used for further investigations into the correlation between thyroidal exposure to 131I and the outcome of radioiodine therapy of benign thyroid disease as well as the development of dosing recommendations.
Entities:
Keywords:
Benign thyroid disorders; Population model; Radioiodine uptake; Variability
Authors: S J Bonnema; S Fast; V E Nielsen; H Boel-Jørgensen; P Grupe; P B Andersen; L Hegedüs Journal: J Endocrinol Invest Date: 2010-09-09 Impact factor: 4.256
Authors: Douglas S Ross; Henry B Burch; David S Cooper; M Carol Greenlee; Peter Laurberg; Ana Luiza Maia; Scott A Rivkees; Mary Samuels; Julie Ann Sosa; Marius N Stan; Martin A Walter Journal: Thyroid Date: 2016-10 Impact factor: 6.568
Authors: Dunstana R Melo; Aaron B Brill; Pat Zanzonico; Paolo Vicini; Brian Moroz; Deukwoo Kwon; Stephanie Lamart; Alina Brenner; André Bouville; Steven L Simon Journal: Radiat Res Date: 2015-11-18 Impact factor: 2.841